Citations

Clear

3030 citation(s) found for "Susan, M".

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
Aggarwal, Rahul , Hillman, David W. , Xiao, Han , Picus, Joel , Taplin, Mary‐Ellen , Dorff, Tanya B. , Appleman, Leonard J. , Weckstein, Douglas, Patnaik, Akash , Bryce, Alan H. , Shevrin, Daniel H. , Mohler, James L. , Anderson, D. Mark , Tan, Alan , Halabi, Susan , Dooley, Katharine , O’Brien, Patrick, Ryan, Charles J. , Eggener, Scott E. , Dakhil, Shaker R. , Smith, Raymond E., Gartrell, Benjamin A. , Fagbemi, Seth O., Mowat, Rex B., Hashemi, Neda , Humeniuk, Michael, Ellerton, John , Olsen, Mark R., Wang, Jennifer , Pascual, Sheila, Randall, James M., Kilari, Deepak , Najera, Jose Eugenio, Rowland, Kendrith M. , Hauke, Ralph J. , Shehadeh, N. J., Curti, Brendan D. , Sheh, Bryant C., Basnet, Alina , Gross, Howard M., Hillman, David W , Xiao, Han , Picus, Joel , Dorff, Tanya , Appleman, Leonard , Patnaik, Akash , Bryce, Alan H , Shevrin, Daniel , Mohler, James , Rao, Arpit , Tagawa, Scott T , Halabi, Susan , Dooley, Katharine , O'Brien, Patrick, Chen, Ronald , Eggener, Scott , Morris, Michael J , Heller, Glenn , Anderson, Daniel, Tagawa, Scott T. , O'Brien, Patrick, Chen, Ronald C. , Morris, Michael J. , Kim, Charles , Whang, Young E. , Farber, Charles R. , King, David, Monk, Paul , Bitting, Rhonda L. , Gupta, Gopal N. , Collins, Timothy, Beer, Tomasz M. , Tate, David J. , Conway, James, Goodman, Michael Moses

Mayo Clinic

Journal of Clinical Oncology | January 24, 2024 | Volume: 42 | Issue: 10 | Pages: 1114-1123

10.1200/jco.23.01157 | PMID 38261983 Get It

PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen receptor antagonist, and abiraterone acetate plus prednisone (AAP) prolong survival in the metastatic setting. We evaluated whether intensification of androgen-deprivation therapy (ADT) improves outcomes in BRPC. PATIENTS AND METHODS PRESTO is a randomized phase III, open-label trial in patients with BRPC and PSA doubling time ≤9 months (ClinicalTrials.gov identifier: NCT03009981 ). Patients were randomly assigned 1:1:1 to receive a finite 52-week treatment course with ADT control, ADT + apalutamide, or ADT + apalutamide + AAP. The primary end point was PSA progression-free survival (PSA-PFS), defined as serum PSA >0.2 ng/mL after treatment completion. RESULTS Five hundred three patients were enrolled. The median PSA was 1.8 ng/mL (IQR, 1.0-3.6). At the first planned interim analysis, both experimental arms significantly prolonged PSA-PFS compared with the control arm (median, 24.9 months for ADT + apalutamide v 20.3 months for ADT; hazard ratio [HR], 0.52 [95% CI, 0.35 to 0.77]; P = .00047; median, 26.0 months for ADT + apalutamide + AAP v 20.0 months for ADT; HR, 0.48 [95% CI, 0.32 to 0.71]; P = .00008). Median time to testosterone recovery did not differ across treatment arms. The most common grade ≥3 adverse event was hypertension (7.5%, 7.4%, and 18% in ADT, ADT + apalutamide, and ADT + apalutamide + AAP arms, respectively). CONCLUSION Intensified AR blockade for a finite duration prolongs PSA-PFS with a manageable safety profile, without adversely affecting time to testosterone recovery. The addition of apalutamide to ADT should be considered in patients with high-risk BRPC.
Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition
Lo, Yungtai , Lester, Susan C. , Lanjewar, Sonali, Laurini, Javier A., Patel, Ami , Bhattarai, Ava, Ustun, Berrin , Harmon, Bryan, Kleer, Celina G. , Ross, Dara S. , Amin, Ali , Wang, Yihong , Bradley, Robert, Turashvili, Gulisa , Zeng, Jennifer , Baum, Jordan , Hakima, Laleh , Harigopal, Malini, Shin, Sandra J. , Abbott, Sara, Jaffer, Shabnam , Badve, Sunil Shankar, Khoury, Thaer , D’Alfonso, Timothy M. , Collins, Victoria , Towne, William S. , Gan, Yujun, Flieder, Andrea, Aldrees, Rana, Ngo, Marie-Hélène , Edema, Ukuemi, Sapna, Fnu , Schnitt, Stuart J. , Fineberg, Susan , Komforti, Miglena, Wang, Yihong , Turashvili, Gulisa , Ellis, Ian O. , Singh, Kamaljeet , Komforti, Miglena K. , Badve, Sunil , Ginter, Paula S. , Nassar, Aziza , Şahin, Ayşegül A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 20, 2024 | Volume: 148 | Issue: 10 | Pages: 1119-1125

10.5858/arpa.2023-0163-oa | PMID 38244086 Get It

Context.— The Nottingham Grading System (NGS) developed by Elston and Ellis is used to grade invasive breast cancer (IBC). Glandular (acinar)/tubule formation is a component of NGS. Objective.— To investigate the ability of pathologists to identify individual structures that should be classified as glandular (acinar)/tubule formation. Design.— A total of 58 hematoxylin-eosin photographic images of IBC with 1 structure circled were classified as tubules (41 cases) or nontubules (17 cases) by Professor Ellis. Images were sent as a PowerPoint (Microsoft) file to breast pathologists, who were provided with the World Health Organization definition of a tubule and asked to determine if a circled structure represented a tubule. Results.— Among 35 pathologists, the κ statistic for assessing agreement in evaluating the 58 images was 0.324 (95% CI, 0.314–0.335). The median concordance rate between a participating pathologist and Professor Ellis was 94.1% for evaluating 17 nontubule cases and 53.7% for 41 tubule cases. A total of 41% of the tubule cases were classified correctly by less than 50% of pathologists. Structures classified as tubules by Professor Ellis but often not recognized as tubules by pathologists included glands with complex architecture, mucinous carcinoma, and the “inverted tubule” pattern of micropapillary carcinoma. A total of 80% of participants reported that they did not have clarity on what represented a tubule. Conclusions.— We identified structures that should be included as tubules but that were not readily identified by pathologists. Greater concordance for identification of tubules might be obtained by providing more detailed images and descriptions of the types of structures included as tubules.
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024
Schmults, Chrysalyne D. , Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad , Amini, Arya , Bibee, Kristin , Bolotin, Diana, Chen, Pei-Ling , DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Harms, Kelly L. , Lukens, John N. , Manber, Susan, Mark, Lawrence A. , Medina, Theresa , Nehal, Kishwer S. , Patel, Tejesh , Rich, Jason T. , Shaha, Ashok R. , Thomas, Valencia D., Tomblinson, Courtney M. , Venkat, Puja , Xu, Yaohui , Yu, Siegrid S., McCullough, Beth, Espinosa, Sara, Sekulić, Aleksandar , Alam, Murad , Bordeaux, Jeremy S. , Contreras, Carlo M. , Donigan, Jessica M. , Ho, Alan L. , Medina, Theresa Michelle , Nghiem, Paul , Olino, Kelly L. , Park, Soohyung , Puzanov, Igor , Sekulic, Aleksander , Srivastava, Divya , Tomblinson, Courtney, Yusuf, Mehran Behruj

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 19, 2024 | Volume: 22 | Issue: 1D | Pages: 1-11

10.6004/jnccn.2024.0002 | PMID 38244274 Get It

The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments from expert review from panel members, institutional review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled “Clinical N0 Disease, Locally Advanced MCC.” This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term “nonsurgical” by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Jahangir, Chowdhury Arif , Page, David B. , Broeckx, Glenn , Gonzalez, Claudia Aura, Burke, Caoimbhe, Murphy, Clodagh, Reis‐Filho, Jorge S. , Gupta, Rajarsi , Vieth, Michael, Hida, Akira I. , Kahila, Mohamed M. , Kos, Zuzana , Verbandt, Sara , Thagaard, Jeppe , Khiroya, Reena, Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Portela, Flávio Luis Dantas , Deman, Frederik , Dudgeon, Sarah , Elghazawy, Mahmoud , Fernandez‐Martín, Claudio , Fineberg, Susan , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hartman, Johan , Hewitt, Stephen M. , Husain, Zaheed, Irshad, Sheeba , Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Khramtsov, Andrey , Kirtani, Pawan , Korski, Konstanty, Scott, Ely, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Durga, Kharidehal, Mittal, Shachi , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Hytopoulos, Evangelos, Mahon, Sarah, Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Verghese, Gregory , Viale, Giuseppe , Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Bartlett, John M.S. , Loibl, Sibylle , Loi, Sherene , Stovgaard, Elisabeth Specht , Salgado, Roberto , Gupta, Rajarsi R , Chardas, Alexandros , Dantas Portela, Flavio Luis , Elghazawy, Mahmoud , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Hart, Steven N , Hartman, Johan , Kataoka, Tatsuki R , Rau, Tilman T , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Lennerz, Jochen , Loi, Sherene , Reis-Filho, Jorge S , Acs, Balazs , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , Ly, Amy , Harms, Paul W. , Diest, P. J. van , AbdulJabbar, Khalid , Adams, Sylvia , Almeida, Jonas S. , Ardalan, Farid Azmoudeh , Badve, Sunil , Hardas, Alexandros , Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Janssen, Emiel A. M. , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Aktürk, Güray , Kovács, Anikó , Lerousseau, Marvin , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Moore, David , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rajpoot, Nasir , Rapoport, Bernardo L. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sughayer, Maher A. , Sur, Daniel Genel , Symmans, W. Fraser , Teuwen, Jonas , Tran, William T, Laak, Jeroen van der , Yuan, Yinyin , Denkert, Carsten , Savas, Peter Stephen , Gallagher, William M. , Rahman, Arman

Mayo Clinic

The Journal of Pathology | January 17, 2024 | Volume: 262 | Issue: 3 | Pages: 271-288

10.1002/path.6238 | PMID 38230434 Get It

Abstract Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high‐throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi‐marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
Cerhan, James R. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Habermann, Thomas M. , Jaye, David L. , Burack, Richard , McDonnell, Timothy J. , Vega, Francisco , Chapman, Jennifer R. , Leonard, John P. , Bernal‐Mizrachi, Leon , Alderuccio, Juan Pablo , Riska, Shaun M., Gysbers, Brianna, Lunde, Julianne J. , Reicks, Tanner W., Ayers, Amy , O’Leary, Colin B. , Yost, Kathleen J. , Nowakowski, Grzegorz S. , Ruan, Jia , Koff, Jean L. , Thompson, Carrie A. , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Martin, Peter W., Flowers, Christopher R. , Burack, W Richard , Syrbu, Sergei , Vij, Kiran R , Bernal-Mizrachi, Leon , Witzig, T.E. , Weiner, George , Wang, Yucai , Alderuccio, Juan Pablo , Slager, Susan L , Liu, Hongfang , Chihara, Dai , Koff, Jean L , Casulo, Carla , Thompson, Carrie A , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Vega, Francisco , Link, Brian K , Habermann, Thomas , Jaye, David L , Syrbu, Sergei , Inghirami, Giorgio , Farooq, Umar , Witzig, Thomas E. , Weiner, George J. , Wang, Yucai , Slager, Susan L. , Larson, Melissa C. , Liu, Hongfang , Chihara, Dai , Casulo, Carla , Kahl, Brad S. , Nastoupil, Loretta J. , Martin, Peter

Mayo Clinic

American Journal of Hematology | January 13, 2024 | Volume: 99 | Issue: 3 | Pages: 408-421

10.1002/ajh.27202 | PMID 38217361 Get It

AbstractTo address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African‐Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population‐based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population‐based SEER rates for indolent B‐cell (follicular and marginal zone) and T‐cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B‐cell subtypes (diffuse large B‐cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
Abdelbaky, Salma , Giacopelli, Brian , Rabe, Kari G. , Yamaguchi, Kyoko , Wu, Yue-Zhong, Yan, Huihuang , Shanafelt, Tait D. , Parikh, Sameer A. , Hampel, Paul J. , Brown, Sochilt , Vachon, Celine M. , Hanson, Curtis A. , Parker, Alexander S. , Oakes, Christopher C. , Ding, Wei , Hampel, Paul J , Cerhan, James R , Vachon, Celine M. , Kay, Neil E , Braggio, Esteban , Slager, Susan L , Oakes, Christopher C , Chaffee, Kari G. , Ding, Wei , Parikh, Sameer A , Shanafelt, Tait D , Ding, Wei , Cerhan, James R. , Kay, Neil E. , Braggio, Esteban , Slager, Susan L.

Mayo Clinic

Blood | January 9, 2024 | Volume: 143 | Issue: 17 | Pages: 1752-1757

10.1182/blood.2023022180 | PMID 38194687 Get It

Abstract Monoclonal B-cell lymphocytosis (MBL) progresses to chronic lymphocytic leukemia (CLL) requiring therapy at 1% to 5% per year. Improved prediction of progression would greatly benefit individuals with MBL. Patients with CLL separate into 3 distinct epigenetic subtypes (epitypes) with high prognostic significance, and recently the intermediate epitype has been shown to be enriched for high-risk immunoglobulin lambda variable (IGLV) 3-21 rearrangements, impacting outcomes for these patients. Here, we employed this combined strategy to generate the epigenetic and light chain immunoglobulin (ELCLV3-21) signature to classify 219 individuals with MBL. The ELCLV3-21 high-risk signature distinguished MBL individuals with a high probability of progression (39.9% and 71.1% at 5 and 10 years, respectively). ELCLV3-21 improved the accuracy of predicting time to therapy for individuals with MBL compared with other established prognostic indicators, including the CLL international prognostic index (c-statistic, 0.767 vs 0.668, respectively). Comparing ELCLV3-21 risk groups in MBL vs a cohort of 226 patients with CLL revealed ELCLV3-21 high-risk individuals with MBL had significantly shorter time to therapy (P = .003) and reduced overall survival (P = .03) compared with ELCLV3-21 low-risk individuals with CLL. These results highlight the power of the ELCLV3-21 approach to identify individuals with a higher likelihood of adverse clinical outcome and may provide a more accurate approach to classify individuals with small B-cell clones.
Using the Operating Room Black Box to Assess Surgical Team Member Adaptation Under Uncertainty
Incze, Taylor , Pinkney, Sonia, Li, Cherryl, Hameed, Usmaan , Grantcharov, Teodor , Trbovich, Patricia , Hallbeck, M. Susan

Mayo Clinic

Annals of Surgery | January 9, 2024 | Volume: 280 | Issue: 1 | Pages: 75-81

10.1097/sla.0000000000006191 | PMID 38193296 Get It

Objective: Identify how surgical team members uniquely contribute to teamwork and adapt their teamwork skills during instances of uncertainty. Background The importance of surgical teamwork in preventing patient harm is well documented. Yet, little is known about how key roles (nurse, anesthesiologist, surgeon, and medical trainee) uniquely contribute to teamwork during instances of uncertainty, particularly when adapting to and rectifying an intraoperative adverse event (IAE). Methods: Audiovisual data of 23 laparoscopic cases from a large community teaching hospital were prospectively captured using OR Black Box. Human factors researchers retrospectively coded videos for teamwork skills (backup behavior, coordination, psychological safety, situation assessment, team decision-making, and leadership) by team role under 2 conditions of uncertainty: associated with an IAE versus no IAE. Surgeons identified IAEs. Results: In all, 1015 instances of teamwork skills were observed. Nurses adapted to IAEs by expressing more backup behavior skills (5.3× increase; 13.9 instances/hour during an IAE vs 2.2 instances/hour when no IAE) while surgeons and medical trainees expressed more psychological safety skills (surgeons: 3.6× increase; 30.0 instances/hour vs 6.6 instances/hour and trainees: 6.6× increase; 31.2 instances/hour vs 4.1 instances/hour). All roles expressed fewer situation assessment skills during an IAE versus no IAE. Conclusions: OR Black Box enabled the assessment of critically important details about how team members uniquely contribute during instances of uncertainty. Some teamwork skills were amplified, while others dampened when dealing with IAEs. The knowledge of how each role contributes to teamwork and adapts to IAEs should be used to inform the design of tailored interventions to strengthen interprofessional teamwork.
Implicit Bias and Health Disparities Education in the Neonatal Intensive Care Unit
Dyess, Nicolle Fernández , Carr, Cara Beth , Mavis, Stephanie C. , Caruso, Catherine G. , Izatt, Susan , French, Heather , Bonachea, Elizabeth , Gray, Megan M , Dadiz, Rita

Mayo Clinic

American Journal of Perinatology | January 9, 2024 | Volume: 41 | Issue: 12 | Pages: 1634-1644

10.1055/a-2240-1979 | PMID 38190976 Get It

Objective This study aimed to characterize implicit bias (IB) and health disparities (HD) education in neonatal–perinatal medicine (NPM), including current educational opportunities, resources, and barriers. Study Design A national web-based survey was sent to NPM fellows, neonatologists, and frontline providers after iterative review by education experts from the National Neonatology Curriculum Committee. Quantitative data were analyzed with chi-square and Fisher's exact tests. Qualitative data were evaluated using thematic analysis. Results Of the 452 NPM survey respondents, most desired additional IB (76%) and HD (83%) education. A greater proportion of neonatologists than fellows received IB (83 vs. 57%) and HD (87 vs. 74%) education. Only 41% of neonatologists reported that their institution requires IB training. A greater proportion of fellows than neonatologists expressed dissatisfaction with the current approaches for IB (51 vs. 25%, p < 0.001) and HD (43 vs. 25%, p = 0.015) education. The leading drivers of dissatisfaction included insufficient time spent on the topics, lack of specificity to NPM, inadequate curricular scope or depth, and lack of local educator expertise. A minority of faculty who were tasked to educate others have received specific educator training on IB (21%) and HD (16%). Thematic analysis of survey free-text responses identified three main themes on the facilitators and barriers to successful IB and HD education: individual, environmental, and curricular design variables. Conclusion NPM trainees and neonatologists desire tailored, active, and expert-guided IB and HD education. Identified barriers are important to address in developing an effective IB/HD curriculum for the NPM community. Key Points
AMCP Market Insights Health Plan Best Practice: Implementing continuous glucose monitoring to improve patient outcomes in diabetes
Pangrace, Michael , Dolan, Sheri, Grace, Thomas , Greene, Estay, Long, Eric C., McClelland, Scott, Moore, Josh, Morgan, Diane E., Mullins, Heather, Wescott, Susan, Long, Eric, McClelland, Scott

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | January 8, 2024 | Volume: 30 | Issue: 1-a Suppl | Pages: S1-S15

10.18553/jmcp.2024.30.1-a.s1 | PMID 38190244 Get It

Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies
Li, Yafang , Xiao, Xiangjun , Li, Jianrong , Han, Younghun , Cheng, Chao , Fernandes, Gail , Slewitzke, Shannon E. , Rosenberg, Susan M. , Zhu, Meng , Byun, Jinyoung , McKay, James , Lam, Stephen , Chen, Chu , Bojesen, Stig E. , Landi, Maria Teresa , Risch, Angela , Wichmann, H-Erich , Goodman, Gary E. , Field, John K. , Shete, Sanjay , Liu, Geoffrey , Andrew, Angeline S. , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E. , Aldrich, Melinda C. , Schwartz, Ann G. , Gorlov, Ivan , Purrington, Kristen S. , Liu, Yanhong , Mandal, Diptasri , Gaba, Colette , Brennan, Paul , Xia, Jun , Fernandes, Gail F , Bossé, Yohan , McKay, James , Albanes, Demetrius , Lam, Stephen , Tardón, Adonina , Chen, Chu , Bojesen, Stig E , Landi, Maria T , Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Wichmann, H-Erich , Christiani, David C. , Rennert, Gad , Arnold, Susanne M , Goodman, Gary E , Field, John K , Davies, Michael P A , Shete, Sanjay , Marchand, Loïc Le , Liu, Geoffrey , Hung, Rayjean J , Andrew, Angeline S , Kiemeney, Lambertus A , Sun, Ryan , Zienolddiny, Shanbeh , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E , Cox, Angela , Hong, Yun‐Chul , Lazarus, Philip J. , Schabath, Matthew B , Aldrich, Melinda C , Schwartz, Ann G , Gorlov, Ivan , Purrington, Kristen S , Yang, Ping , Liu, Yanhong , Wilson, Richard K , Pinney, Susan M , Mandal, Diptasri , Willey, James C , Brennan, Paul , Xia, Jun , Shen, Hongbing , Amos, Christopher I , Han, Younghun , Cheng, Chao , Byun, Jinyoung , Bossé, Yohan , Albanes, Demetrius , Tardón, Adonina , Johansson, Mattias , Bickeböller, Heike , Rennert, Gad , Arnold, Susanne M. , Davies, Michael P.A. , Marchand, Loı̈c Le , Hung, Rayjean J. , Kiemeney, Lambertus A. , Zienolddiny, Shanbeh , Cox, Angela , Schabath, Matthew B. , Yang, Ping , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Willey, James C. , Shen, Hongbing , Amos, Christopher I.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 5, 2024 | Volume: 33 | Issue: 3 | Pages: 389-399

10.1158/1055-9965.epi-23-0613 | PMID 38180474 Get It

Abstract Background: Clinical, molecular, and genetic epidemiology studies displayed remarkable differences between ever- and never-smoking lung cancer. Methods: We conducted a stratified multi-population (European, East Asian, and African descent) association study on 44,823 ever-smokers and 20,074 never-smokers to identify novel variants that were missed in the non-stratified analysis. Functional analysis including expression quantitative trait loci (eQTL) colocalization and DNA damage assays, and annotation studies were conducted to evaluate the functional roles of the variants. We further evaluated the impact of smoking quantity on lung cancer risk for the variants associated with ever-smoking lung cancer. Results: Five novel independent loci, GABRA4, intergenic region 12q24.33, LRRC4C, LINC01088, and LCNL1 were identified with the association at two or three populations (P &lt; 5 × 10−8). Further functional analysis provided multiple lines of evidence suggesting the variants affect lung cancer risk through excessive DNA damage (GABRA4) or cis-regulation of gene expression (LCNL1). The risk of variants from 12 independent regions, including the well-known CHRNA5, associated with ever-smoking lung cancer was evaluated for never-smokers, light-smokers (packyear ≤ 20), and moderate-to-heavy-smokers (packyear &gt; 20). Different risk patterns were observed for the variants among the different groups by smoking behavior. Conclusions: We identified novel variants associated with lung cancer in only ever- or never-smoking groups that were missed by prior main-effect association studies. Impact: Our study highlights the genetic heterogeneity between ever- and never-smoking lung cancer and provides etiologic insights into the complicated genetic architecture of this deadly cancer.